Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

Morning finger stiffness can be a subtle sign of early arthritis. Learn what to watch for and how early intervention can help ...

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints ...

Medically reviewed by Anita C. Chandrasekaran, MD Psoriatic arthritis (PsA) is a chronic (long-lasting) condition that ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Scientists are urging quicker diagnosis and treatment of psoriatic arthritis to prevent long-term harm to patients. Psoriatic ...